Literature DB >> 9645712

A corticotropin-releasing hormone type I receptor antagonist delays parturition in sheep.

E C Chan1, J Falconer, G Madsen, K C Rice, E L Webster, G P Chrousos, R Smith.   

Abstract

In sheep, corticotropin-releasing hormone (CRH) can stimulate the fetal release of ACTH to produce a cortisol surge which leads to the onset of parturition. We tested the hypothesis that fetal CRH is a primary factor in the onset of parturition in sheep by using a Type I CRH receptor antagonist, antalarmin, to block the endogenous action of CRH. Pregnant ewes were cannulated at 130-135 days of gestation. Five catheters were placed into the amniotic sac, fetal femoral artery, fetal tarsal vein, maternal jugular vein and carotid artery. After 5 days' recovery, blood samples from maternal and fetal vessels were collected at the following times: a day before the start of infusion, at [-1, 0, 1, 2, 4, 8 and 24]h, on the first day of infusion, and thereafter daily throughout a 10-day infusion. Animals (n=6 per group) received infusions into a fetal vein of either a vehicle comprising 1:1 mixture of ethanol and polyethoxylated castor oil (Cremophor EL) or antalarmin (50 g/L) in the vehicle at a rate of 0.3 mL/h. The plasma samples were assayed for ACTH and cortisol using commercial RIA kits. Fetuses infused with vehicle delivered at a mean gestational age of 141.8 +/- 0.9 days compared with antalarmin-infused sheep at 148.8 +/- 1.6 days (P = 0.0036, unpaired Student's t-test). Fetal ACTH and cortisol did not change in the antalarmin-infused sheep after 3 days' infusion compared to significant increases in vehicle-infused sheep (P=0.004 and P = 0.016 respectively, ANOVA). These data show that CRH receptor antagonism in the fetus can delay the onset of parturition. It supports the hypothesis that hypothalamic CRH drives fetal production of ACTH and is essential for the onset of parturition triggered by a surge in fetal cortisol.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9645712     DOI: 10.1210/endo.139.7.6189

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Treatment with a CRH-R1 antagonist prevents stress-induced suppression of the central neural drive to the reproductive axis in female macaques.

Authors:  S M Herod; C R Pohl; J L Cameron
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-09-07       Impact factor: 4.310

Review 2.  Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.

Authors:  Megan C Chapter; Caitlin M White; Angela DeRidder; Wayne Chadwick; Bronwen Martin; Stuart Maudsley
Journal:  Pharmacol Ther       Date:  2009-08-15       Impact factor: 12.310

3.  Ecological momentary assessment of maternal cortisol profiles over a multiple-day period predicts the length of human gestation.

Authors:  Sonja Entringer; Claudia Buss; Judith Andersen; Aleksandra Chicz-DeMet; Pathik D Wadhwa
Journal:  Psychosom Med       Date:  2011-06-23       Impact factor: 4.312

4.  Positive association of serum interleukin-1beta and CRH levels in women with pre-term labor.

Authors:  N Vitoratos; G Mastorakos; A Kountouris; K Papadias; G Creatsas
Journal:  J Endocrinol Invest       Date:  2007-01       Impact factor: 4.256

Review 5.  The emerging role of peripheral corticotropin-releasing hormone (CRH).

Authors:  I Ilias; G Mastorakos
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

6.  Elevated midpregnancy corticotropin-releasing hormone is associated with prenatal, but not postpartum, maternal depression.

Authors:  J W Rich-Edwards; A P Mohllajee; K Kleinman; M R Hacker; J Majzoub; R J Wright; M W Gillman
Journal:  J Clin Endocrinol Metab       Date:  2008-02-26       Impact factor: 5.958

Review 7.  Maternal history of childhood sexual abuse and preterm birth: an epidemiologic review.

Authors:  Adaeze C Wosu; Bizu Gelaye; Michelle A Williams
Journal:  BMC Pregnancy Childbirth       Date:  2015-08-15       Impact factor: 3.007

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.